Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Data Entry and Source Documentation in Clinical Phase – V 2.0

Posted on By

BA-BE Studies: SOP for Data Entry and Source Documentation in Clinical Phase – V 2.0

Standard Operating Procedure for Data Entry and Source Documentation in Clinical Phase of BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/091/2025
Supersedes SOP/BA-BE/091/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized approach for the documentation of clinical data at source and its subsequent entry into Case Report Forms (CRFs) or electronic systems during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, ensuring traceability, accuracy, and compliance with ALCOA+ principles.

2. Scope

This SOP applies to all clinical personnel involved

in source data documentation, CRF/eCRF data entry, data verification, and clinical quality assurance during the conduct of BA/BE studies.

3. Responsibilities

  • Study Nurse: Documents observations and procedures in real-time on source documents.
  • Clinical Research Coordinator (CRC): Verifies completeness and consistency of source documents and performs CRF data entry.
  • Principal Investigator (PI): Reviews and signs off on key clinical data and source-CRF correlation.
  • QA Officer: Audits data trail from source to CRF and ensures ALCOA+ compliance.
See also  BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period - V 2.0

4. Accountability

The Study Director is accountable for ensuring that all source documents and CRFs are handled according to applicable regulatory guidelines, and that data integrity is maintained throughout the clinical phase.

5. Procedure

5.1 Source Documentation

  1. Use only approved source templates pre-printed with study ID, subject ID, and visit date.
  2. Document the following at source:
    • Volunteer identity and informed consent status
    • Vital signs
    • Pre- and post-dose assessments
    • Adverse events
    • Dosing records
    • Sample collection times and personnel
  3. All entries must be:
    • Legible
    • Signed and dated
    • Made in blue or black ink
  4. Corrections must follow GCP standards: strike through, write correct entry, date and initial.

5.2 CRF Data Entry

  1. Transfer data from source to CRFs after each study activity or at end of day.
  2. Ensure that:
    • CRF data matches the source exactly
    • Blank fields are marked “NA”
    • Corrections follow SOP for CRF amendments
  3. Document and explain any discrepancies using Annexure-1: Source-CRF Discrepancy Log.
See also  BA-BE Studies: SOP for Laboratory Safety Tests Prior to Dosing - V 2.0

5.3 Electronic Data Capture (eDC)

  1. If using eCRFs, enter data directly into the validated system with individual login credentials.
  2. Audit trails must remain intact and accessible for inspection.

5.4 Quality Control and Review

  1. CRC must perform cross-checks of 100% of critical fields (e.g., date/time of dosing, AE records).
  2. PI to review and sign off on CRFs and summaries (Annexure-2: CRF Verification Log).

5.5 Storage and Confidentiality

  1. Store source documents in subject-wise files secured in a locked room with access logs.
  2. Electronic source and CRFs must be password protected and regularly backed up.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRF: Case Report Form
  • eCRF: Electronic Case Report Form
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, and Available
See also  BA-BE Studies: SOP for Medical History Documentation in Healthy Volunteers - V 2.0

7. Documents

  1. Source-CRF Discrepancy Log – Annexure-1
  2. CRF Verification Log – Annexure-2

8. References

  • ICH E6(R2) – Good Clinical Practice
  • 21 CFR Part 11 – Electronic Records
  • Schedule Y – Drugs and Cosmetics Rules

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Source-CRF Discrepancy Log

Date Subject ID Field Source Value CRF Value Resolution Reviewed By
17/04/2025 VOL-091 Pulse 78 87 Corrected in CRF Dr. Arvind Shah

Annexure-2: CRF Verification Log

Subject ID Date Reviewed Reviewed By Remarks
VOL-091 17/04/2025 Dr. Arvind Shah Complete and accurate

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP GCP Compliance QA Head
17/04/2025 2.0 Added ALCOA+ reference, clarified eCRF and source reconciliation Audit Observation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Creams: SOP for Measuring Viscosity of Cream Formulations – V 2.0
Next Post: Analytical Method Development: Use of Design of Experiments (DoE) in Method Development – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version